ArticleCureus2026
Under the Surface: A Rare Case of the En Coup De Sabre Subtype of Linear Morphea in the Rio Grande Valley.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localized scleroderma, also referred to as 'morphea,' is a rare autoimmune disorder that affects the superficial layers of the skin and is characterized by both erythematous and bruise-like lesions with signs of central skin tightening or sclerosis; deeper lesions may be identified as edematous, erythematous plaques in the absence of well-defined borders. A subtype named en coup de sabre (ECDS) exists in the classification of linear morphea and presents with a linear induration on either the face or scalp. Our patient is a 21-year-old Hispanic female initially residing outside of the South Texas region who experienced an onset of skin thickening and blisters on her right leg in April of 2023 after returning from Europe. Initially, she was diagnosed as having stasis dermatitis, but due to progression of her cutaneous symptoms, a skin biopsy was performed in September of 2023, which confirmed a diagnosis of morphea. After 10 months of initial treatment with a dermatologist outside of South Texas, she presented to the UT Health Rio Grande Valley (UTRGV) dermatology specialty clinic (Edinburg, TX, USA) with new and evolving skin plaques across her body, along with a forehead lesion that was consistent with the ECDS subtype of linear morphea. During this time, care was also formally established with local rheumatology and wound care specialists who had a pivotal role in the management of her condition. This case discusses the variability in clinical presentation of morphea, its mixed nature of lesions, its progression, its varied response to medical therapy, and the need for multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.